Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.
about
Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell CarcinomaIs There Still Room for Cancer Vaccines at the Era of Checkpoint InhibitorsMonitoring of the Immune Dysfunction in Cancer PatientsTLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients.Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.Induction of resident memory T cells enhances the efficacy of cancer vaccineIntralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumoursPotential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer.The importance of correctly timing cancer immunotherapy.Human Papillomavirus Downregulates the Expression of IFITM1 and RIPK3 to Escape from IFNγ- and TNFα-Mediated Antiproliferative Effects and Necroptosis.Human papillomavirus-associated cutaneous disease burden in human immunodeficiency virus (HIV)-positive patients: the role of human papillomavirus vaccination and a review of the literature.Mouse papillomavirus infection persists in mucosal tissues of an immunocompetent mouse strain and progresses to cancer.Glycolipid-peptide conjugate vaccines enhance CD8+ T cell responses against human viral proteins.HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia.The dawn of vaccines for cancer prevention.Photochemical Internalization of Peptide Antigens Provides a Novel Strategy to Realize Therapeutic Cancer Vaccination.Targeting Head and Neck Cancer by Vaccination.Membrane Active Peptides and Their Biophysical CharacterizationNext Generation Cancer Vaccines-Make It Personal!
P2860
Q28071998-FEB47059-725C-4689-8A0B-4FE5071E17C3Q28072532-03DFD7F9-D5DD-4933-9AD0-0FA1EE573C04Q28072712-2F7B1492-D804-4E4D-B150-1AC0AC3DD3B5Q30841163-A0BE935B-09D2-4569-9577-8AAFA4838EF6Q33440805-056D4E51-8DE7-428E-B520-92DABE35A732Q33761198-81D4BE87-B263-46DA-9C03-77A77F7B9D1AQ36638606-783AE09D-905B-47B3-B0DE-53A84DC31131Q37399278-59F6C2A7-E020-4380-9149-42E988AD3F00Q38995979-42A661C9-B776-4D08-87DD-26E05B41FCF9Q40422515-FEE31865-4A2A-46D7-8CB0-E961566C20E5Q45324643-DE895E00-6125-4A9C-B66E-44269B5A3197Q47136512-84252DD2-0A0B-4091-85F4-E0DB85EB62A9Q47144502-A92340C6-12ED-4FFC-AA54-87DD0762B60FQ47797636-9401B4EC-1BD4-40F8-8961-45951E33A270Q49566629-CC6C6058-E8B9-40C5-B653-51323802FB97Q52316326-05BBCF5D-E7DB-4514-AB48-7D083BB2CF33Q54217605-BF95DFA6-6741-403E-808E-CB488BE41DABQ58717273-B12C4799-CEB4-41CE-924E-01C9989C6AFAQ58791982-043F1E5B-D769-43F3-9931-50ED5B6A40F6
P2860
Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Vaccination against Oncoprotei ...... rength of the T-Cell Response.
@en
type
label
Vaccination against Oncoprotei ...... rength of the T-Cell Response.
@en
prefLabel
Vaccination against Oncoprotei ...... rength of the T-Cell Response.
@en
P2093
P1476
Vaccination against Oncoprotei ...... trength of the T-Cell Response
@en
P2093
A Rob P M Valentijn
Bart W J Hellebrekers
Cornelis J M Melief
Dorien M A Berends-van der Meer
Edith M G van Esch
Gemma G Kenter
Gertjan J Fleuren
Hans W Nijman
Harry Hollema
Henk W Schreuder
P304
P356
10.1158/1078-0432.CCR-15-2594
P407
P577
2016-01-26T00:00:00Z